Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biopharmaceutics & Drug Disposition|December 7, 2018
Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailabilityNeha Maharao, Jurgen Venitz, Phillip M Gerk
Drug Metabolism Reviews|February 22, 2020
Entering the era of computationally driven drug developmentNeha Maharao, Victor Antontsev, Matthew Wright, et al.
Drug Design, Development and Therapy|July 2, 2020
Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM PlatformNeha Maharao, Victor Antontsev, Hypatia Hou, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2020
Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450Sumit Bansal, Neha Maharao, Mary F Paine, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation PlatformKaushik Chakravarty, Victor G Antontsev, Maksim Khotimchenko, et al.
Pharmacology & Therapeutics|May 10, 2019
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokineticsEmily J Cox, Neha Maharao, Gabriela Patilea-Vrana, et al.
Clinical and Translational Science|April 9, 2025
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy ParticipantsNeha Maharao, Donghong Xu, Tyrell J Simkins, et al.
Clinical and Translational Science|March 5, 2026
Clinical Evaluation of Drug-Drug Interactions With AficamtenNeha Maharao, Donghong Xu, Punag Divanji, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
Pageof 1